Physician profile
Mark Douglas Smith
NPI 1881676047
$13,041.65
in general payments reported to CMS, 2019-2025
27 companies · $2,541 in 2025
The $2,541 reported for 2025 was more than what 84% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $51.10 · 2021: $351 · 2022: $690 · 2023: $157 · 2024: $7,879 · 2025: $2,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Travel and Lodging: $2,147 · Food and Beverage: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Travel and Lodging | $2,146.71 |
| Food and Beverage | $1,430.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,244.14 | 2022-2025 | |
| Fujifilm Healthcare Americas Corporation | $750.80 | 2019-2021 | |
| Davol INC. | $681.00 | 2019-2025 | Phasix Mesh |
| Organogenesis INC. | $235.66 | 2019-2022 | |
| Boston Scientific Corporation | $180.90 | 2020-2024 | Spyglass Discover |
| Smith+Nephew, INC. | $176.15 | 2019-2024 | Collagenase Santyl, Renasys Touch |
| Kci USA, INC. | $131.40 | 2019-2023 | Promogran Prisma, Activ.A.C. |
| Takeda Pharmaceuticals U.S.A., INC. | $95.74 | 2022-2024 | Gattex, Eohilia |
| Medtronic, INC. | $91.27 | 2022 | |
| Tela Bio, INC. | $69.16 | 2024 | Ovitex 2s |
| Pacira Pharmaceuticals Incorporated | $58.58 | 2024-2025 | Exparel |
| Biotronik INC. | $38.19 | 2019 | |
| Shire North American Group INC | $27.16 | 2019 | |
| Csl Behring | $26.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.77 | 2024 | Uzedy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $23.04 | 2019 | |
| Amgen INC. | $23.03 | 2023 | Repatha |
| Aroa Biosurgery Incorporated | $21.78 | 2019 | |
| Tei Biosciences INC | $19.51 | 2019 | |
| Integra Lifesciences Corporation | $19.16 | 2024 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Allergan, INC. | $17.80 | 2021 | |
| Heron Therapeutics, INC. | $16.68 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.25 | 2025 | Voquezna |
| Next Science LLC | $15.24 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $14.51 | 2019 | |
| Osiris Therapeutics INC. | $11.98 | 2019 | |
| Olympus America INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.